Ken Griffin Vigil Neuroscience, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Vigil Neuroscience, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,507,192 shares of VIGL stock, worth $4.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,507,192

Previous 1,442,468 4.49%

Holding current value

$4.57 Million

Previous $4.9 Million 48.37%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.53 - $4.0 $99,027 - $258,896	64,724 Added 4.49%	1,507,192 $2.53 Million
Q3 2024 Nov 14, 2024	SELL	$2.92 - $4.65 $2,017 - $3,213	-691 Reduced 0.05%	1,442,468 $4.9 Million
Q2 2024 Aug 14, 2024	SELL	$2.51 - $4.66 $1.81 Million - $3.37 Million	-722,652 Reduced 33.37%	1,443,159 $5.77 Million
Q1 2024 May 15, 2024	BUY	$2.68 - $3.63 $10,476 - $14,189	3,909 Added 0.18%	2,165,811 $7.39 Million
Q4 2023 Feb 14, 2024	SELL	$2.97 - $8.6 $12,506 - $36,214	-4,211 Reduced 0.19%	2,161,902 $7.31 Million
Q3 2023 Nov 14, 2023	SELL	$4.8 - $9.92 $68,212 - $140,973	-14,211 Reduced 0.65%	2,166,113 $11.7 Million
Q2 2023 Aug 14, 2023	BUY	$8.11 - $10.54 $150,262 - $195,285	18,528 Added 0.86%	2,180,324 $20.5 Million
Q1 2023 May 15, 2023	SELL	$8.77 - $12.7 $18,592 - $26,924	-2,120 Reduced 0.1%	2,161,796 $21.2 Million
Q4 2022 Feb 14, 2023	SELL	$8.74 - $15.99 $22,295 - $40,790	-2,551 Reduced 0.12%	2,163,916 $27 Million
Q3 2022 Nov 14, 2022	BUY	$2.37 - $9.61 $3,391 - $13,751	1,431 Added 0.07%	2,166,467 $19.7 Million

Others Institutions Holding VIGL

# of Institutions

Shares Held

26.9M

Call Options Held

Put Options Held

View Full List

About Vigil Neuroscience, Inc.

Ticker VIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,268,600
Market Cap $85.7M
Description
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...

More about VIGL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account